What Happened

Ona Therapeutics, a Barcelona-based biotech, secured $87M in Series B funding to advance its antibody-drug conjugate (ADC) pipeline. The funding will support the development of ONA-255 and ONA-389, targeting breast and colorectal cancers with a focus on overcoming drug resistance.

Who Is Affected

This development impacts oncology-focused biotechs, pharmaceutical companies, and investors. Companies like AstraZeneca and Daiichi Sankyo, which dominate the ADC space, may face new competition. Investors, including Columbus Venture Partners and Mérieux Equity Partners, are backing Ona's innovative approach.

Market Impact

• Expands the ADC market, particularly in breast and colorectal cancers.
• Introduces new targets to address drug resistance, a major challenge in oncology.
• Positions Ona as a potential partner or acquisition target for larger pharma companies.

What to Watch

Monitor Ona's progress with ONA-255 in clinical trials and its potential expansion into other cancer types. Watch for partnerships or licensing deals with established players in the ADC space, such as AstraZeneca or Daiichi Sankyo.